Why the study?
Reperfusion post-AMI triggers inflammatory and oxidative damage contributing to heart failure, but therapeutic anti-inflammatory and antioxidant agents successful in preclinical studies have failed in clinical trials.
Design
Review
Authors
Loading...
MPO inhibition remains investigational post-AMI; leaves open whether neutrophil-derived myeloperoxidase prevents clinical heart failure.
Key points are not available for this paper at this time.
Kazzi et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: